

Mika Juhani VÃ¤limÃ¤ki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7031291/publications.pdf>

Version: 2024-02-01

11
papers

268
citations

1305906

8
h-index

1526636

10
g-index

11
all docs

11
docs citations

11
times ranked

449
citing authors

#	ARTICLE	IF	CITATIONS
1	GATA4-targeted compounds modulate cardiac subtype cell differentiation in dual reporter stem cell line. <i>Stem Cell Research and Therapy</i> , 2021, 12, 190.	2.4	7
2	Domain-Independent Inhibition of CBP/p300 Attenuates α -Synuclein Aggregation. <i>ACS Chemical Neuroscience</i> , 2021, 12, 2273-2279.	1.7	7
3	Targeting GATA4 for cardiac repair. <i>IUBMB Life</i> , 2020, 72, 68-79.	1.5	19
4	GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes. <i>Archives of Toxicology</i> , 2020, 94, 2113-2130.	1.9	18
5	Synthesis, Identification, and Structure-Activity Relationship Analysis of GATA4 and NKX2-5 Protein-Protein Interaction Modulators. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8284-8310.	2.9	18
6	Cardiac Actions of a Small Molecule Inhibitor Targeting GATA4-NKX2-5 Interaction. <i>Scientific Reports</i> , 2018, 8, 4611.	1.6	29
7	Stem cells are the most sensitive screening tool to identify toxicity of GATA4-targeted novel small-molecule compounds. <i>Archives of Toxicology</i> , 2018, 92, 2897-2911.	1.9	26
8	Stem cells are the most sensitive screening tool to identify toxicity of GATA4-targeted small-molecule compounds. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-9-32.	0.0	0
9	Discovery of Small Molecules Targeting the Synergy of Cardiac Transcription Factors GATA4 and NKX2-5. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7781-7798.	2.9	46
10	Nuclear Receptor-Like Structure and Interaction of Congenital Heart Disease-Associated Factors GATA4 and NKX2-5. <i>PLoS ONE</i> , 2015, 10, e0144145.	1.1	25
11	In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart. <i>Biomaterials</i> , 2014, 35, 8394-8405.	5.7	73